DAPAGLOXIT 10MG 10S

About

Dapagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that functions by inhibiting glucose reabsorption in the kidneys, thereby promoting the excretion of glucose in the urine. This action effectively lowers elevated blood glucose levels in adults with type 2 diabetes mellitus. Importantly, dapagliflozin has been shown to provide substantial benefits beyond glycemic control. It significantly reduces the risk of hospitalization for heart failure and cardiovascular death in patients with heart failure, and it also slows the progression of chronic kidney disease. Its multifaceted mechanism contributes to improved cardiovascular and renal outcomes, establishing it as a crucial therapeutic agent for managing type 2 diabetes, heart failure, and chronic kidney disease, often used alongside lifestyle modifications.

Uses

• Management of type 2 diabetes mellitus.
• Reduction of hospitalization for heart failure in adults.
• Reduction of the risk of kidney disease progression in adults with chronic kidney disease.
• Reduction of cardiovascular death in adults with heart failure.

Directions For Use

Take orally once daily in the morning, with or without food, as prescribed by your doctor. Swallow the tablet whole with water.

Benefits

• Effective glycemic control.
• Reduces risk of heart failure hospitalization.
• Slows progression of chronic kidney disease.
• May contribute to modest weight loss.
• Lowers blood pressure.
• Provides cardiovascular protection.

Side Effects

• Genital mycotic infections
• Urinary tract infections (UTIs)
• Increased urination
• Thirst
• Back pain
• Nausea
• Dizziness
• Hypotension
• Ketoacidosis (rare)
• Kidney injury (rare)
• Fournier's gangrene (very rare)
• Hypoglycemia (when combined with other agents)

Safety Measures

• Alcohol - Alcohol consumption may increase the risk of hypoglycemia or diabetic ketoacidosis; use with caution.
• Pregnancy - Not recommended during pregnancy, especially in the second and third trimesters, due to potential adverse effects on fetal kidney development.
• Breastfeeding - Avoid during breastfeeding as dapagliflozin may be excreted in breast milk and could harm the infant.
• Liver - Use with caution in patients with severe hepatic impairment; no dose adjustment needed for mild-moderate.
• Kidney - Dose adjustment may be necessary based on eGFR; not recommended for patients with severe renal impairment or on dialysis.
• Lung - No specific precautions or dose adjustments are typically required for patients with lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.